Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

About this update from Glaukos Corporation

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2774,"height":518,"url":"https://media.zenfs.com/en/business-wire.com/bb7b48a33c0604d873ac823745ebc8e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eMiNfGo7kXNc61.WwcbixQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bb7b48a33c0604d873ac823745ebc8e7","width":960,"height":179},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/oZvxg70Gn2tvBSwatjZ9mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/bb7b48a33c0604d873ac823745ebc8e7","width":1200,"height":224}},"lazy":false},{"type":"text","content":"Regulatory Clearances Support Glaukos’ Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally","length":119,"tagName":"p","attribs":{}},{"type":"text","content":"Marks the Company’s First Regulatory Clearances Under the New EU Regulatory Framework","length":85,"tagName":"p","attribs":{}},{"type":"text","content":"ALISO VIEJO, Calif., June 25, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. Glaukos’ iStent® trabecular micro-bypass stenting platform primarily involves the insertion of a micro-scale surgical devices designed to reduce intraocular pressure by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma.","length":745,"tagName":"p"},{"type":"text","content":""We are pleased to receive these important regulatory clearances for our leading trabecular micro-bypass stenting devices, marking our company’s first approvals under the new EU regulatory framework," said Thomas Burns, Glaukos chairman and chief executive officer. "These important milestones will not only help us maintain and grow our presence in Europe but also advance and accelerate our broader Interventional Glaucoma initiatives globally. We are eager to commen...

More updates from Glaukos Corporation